Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape
Sarah Mcnamee, Neşe Devenot, Meaghan Buisson
JAMA Psychiatry March 29, 2023 DOI: 10.1001/jamapsychiatry.2023.0099 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Citations | 167 |
| Key points | Serious adverse events in psychedelic-assisted therapy trials can be linked to therapist-patient interactions. |
Abstract
This Viewpoint discusses serious adverse events linked to interactions between therapists and patients in trials of psychedelic-assisted therapy.
Citations in the library
Cited by 131
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Extended difficulties following the use of psychedelic drugs: A mixed methods study PLoS One October 24, 2023
- Adverse Events in Studies of Classic Psychedelics JAMA Psychiatry September 4, 2024
- History repeating: guidelines to address common problems in psychedelic science Therapeutic Advances in Psychopharmacology 2023
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment Current Neuropharmacology January 5, 2024
and 126 more in the library
Cites 3
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review Journal of Psychopharmacology August 26, 2022
- Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. Journal of Psychopharmacology 2023